Acura Pharmaceuticals, Inc. Receives Clarification from FDA About Clinical Program; Cash Reserves Update
October 17, 2005 16:48 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., Oct. 17, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced receipt from the United States Food and Drug Administration ("FDA") communications clarifying...
Acura Pharmaceuticals, Inc. Receives Communication from FDA
October 03, 2005 18:07 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., Oct. 3, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced that the Company has received correspondence from the United States Food and Drug Administration...
Acura Pharmaceuticals, Inc. Secures Bridge Funding
September 16, 2005 09:30 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill, Sept. 16, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced that the Company has secured $500,000 under a term Loan Agreement (the "Loan") with Essex...
Acura Pharmaceuticals, Inc. Reports Financial Results For Second Quarter 2005 and Commercial Strategy/Cash Reserves Update
July 14, 2005 16:30 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., July 14, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced a net loss of $1.4 million or $0.06 per share for the quarter ended June 30, 2005 compared to a...
Acura Pharmaceuticals, Inc. Secures Bridge Funding
June 22, 2005 17:33 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., June 22, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced that the Company has secured $1 million under a term Loan Agreement (the "Loan") with Essex...
Acura Pharmaceuticals, Inc. Reports Results for First Quarter 2005
May 02, 2005 16:05 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., May 2, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced net loss of $1,948,000 for the quarter ended March 31, 2005 compared to a net income of $680,000...
Acura Pharmaceuticals, Inc. Announces Commencement of Clinical Trials for Product Candidate No. 2 and Updates Commercial Strategy and Cash Reserves
April 15, 2005 16:00 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., April 15, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced the initiation of a clinical trial for the Company's Product Candidate No. 2. Product Candidate...
Acura Pharmaceuticals, Inc. Reports Financial Results, Development Progress and Strategy Update
February 28, 2005 17:13 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., Feb. 28, 2005 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced a net loss of $2.1 million or $0.09 per share for the three months ending December 31, 2004...
Acura Pharmaceuticals, Inc. Reports Results For Third Quarter 2004, Acceptance of IND Filing by FDA and Commencement of Clinical Trials
November 12, 2004 17:05 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., Nov. 12, 2004 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced a net loss of $(51,480,000) or $(2.35) per share for the quarter ended September 30, 2004...
Acura Pharmaceuticals, Inc. Announces New Stock Symbol
August 17, 2004 11:59 ET
|
Acura Pharmaceuticals Inc.
PALATINE, Ill., Aug. 17, 2004 (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced that the Company's common stock will trade under the symbol "ACUR" effective immediately. This...